Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
World J Diabetes ; 13(11): 940-948, 2022 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-36437863

RESUMO

Non-healing diabetic foot ulcers (DFU) are the most notable and striking complications of diabetes mellitus. More than 25% of nonhealing DFU can ultimately lead to amputation of the lower extremity within 6-18 mo after the first manifestation of the wound. Although wound healing is complex, nutritional status is crucial in soft tissue repair. Malnutrition is highly prevalent and overlooked in patients with diabetes and chronic wounds. Moreover, to date, we do not have clear recommendations or evidence about the use of nutritional supplements for improving wound healing in patients with DFU. In this article the authors briefly analyzed the current evidence on the use of nutritional supplements of proteins or amino acids, fatty acids, probiotics, vitamins, and trace elements in the wound healing process in patients with DFU.

2.
Clin Sci (Lond) ; 134(17): 2337-2352, 2020 09 18.
Artigo em Inglês | MEDLINE | ID: mdl-32857135

RESUMO

BACKGROUND: TNF-related apoptosis-inducing ligand (TRAIL) has attracted attention not only as an anti-cancer agent, but also as a potential treatment for diabetes. Animal studies have shown that TRAIL delivery ameliorated glucose control in type 1 and type 2 diabetes. It is currently unknown whether TRAIL positive effects are maintained in more severe forms of type 2 diabetes, and whether they include renoprotection. Our study aimed at evaluating TRAIL effects in a severe form of type 2 diabetes with nephropathy. MATERIALS AND METHODS: A total of 20 db/db mice were treated with saline or TRAIL twice per week for 12 weeks. In parallel, renal tubular epithelial cells were cultured with TGF-ß1 in the presence and absence of TRAIL, with and without silencing TRAIL-specific receptor (DR5) and leptin receptor. RESULTS: TRAIL did not improve glucose control, but it significantly reduced circulating interleukin (IL)-6 and resistin. In the kidney, TRAIL treatment significantly ameliorated glomerular and tubular morphology with an improvement in kidney function, but no effect on proteinuria. Our in vitro studies on TGF-ß1-treated cells, showed that by binding to DR5, TRAIL rescued normal tubular cell morphology, increasing E-cadherin and reducing α-smooth muscle actin (SMA) expression, with no effects on cell viability. Interestingly, both in vivo and in vitro, TRAIL reduced the accumulation of the autophagy substrate p62. CONCLUSIONS: Our data confirm TRAIL protective effects against organ damage and shed light on to promising anti-fibrotic actions, which are independent of glucose control. TRAIL anti-fibrotic actions might be due to the rescue of autophagy in diabetes.


Assuntos
Nefropatias Diabéticas/patologia , Transição Epitelial-Mesenquimal , Rim/patologia , Ligante Indutor de Apoptose Relacionado a TNF/farmacologia , Fator de Crescimento Transformador beta/farmacologia , Animais , Peso Corporal/efeitos dos fármacos , Nefropatias Diabéticas/metabolismo , Transição Epitelial-Mesenquimal/efeitos dos fármacos , Comportamento Alimentar/efeitos dos fármacos , Fibrose , Regulação da Expressão Gênica/efeitos dos fármacos , Inativação Gênica/efeitos dos fármacos , Glucose/metabolismo , Humanos , Inflamação/patologia , Rim/efeitos dos fármacos , Rim/fisiopatologia , Túbulos Renais/efeitos dos fármacos , Túbulos Renais/patologia , Túbulos Renais/fisiopatologia , Masculino , Camundongos , Ligação Proteica/efeitos dos fármacos , Ratos , Receptores para Leptina/metabolismo , Receptores do Ligante Indutor de Apoptose Relacionado a TNF/metabolismo , Proteína Sequestossoma-1/metabolismo
3.
BMC Endocr Disord ; 18(1): 86, 2018 Nov 19.
Artigo em Inglês | MEDLINE | ID: mdl-30453922

RESUMO

BACKGROUND: Thyroid lymphomas are an exceptional finding in patients with thyroid nodules. Burkitt's lymphoma is one of the rarest and most aggressive forms of thyroid lymphomas, and its prognosis depends on the earliness of medical treatment. Given the rarity of this disease, making a prompt diagnosis can be challenging. For instance, fine-needle aspiration (FNA) cytology, which is the first-line diagnostic test that is performed in patients with thyroid nodules, is often not diagnostic in cases of thyroid lymphomas, with subsequent delay of the start of therapy. CASE PRESENTATION: Here we report the case of a 52-year-old woman presenting with a rapidly enlarging thyroid mass. Thyroid ultrasonography demonstrated a solid hypoechoic nodule. FNA cytology was only suggestive of a lymphoproliferative disorder and did not provide a definitive diagnosis. It is core needle biopsy (CNB) that helped us to overcome the limitations of routine FNA cytology, showing the presence of thyroid Burkitt's lymphoma. Subsequent staging demonstrated bone marrow involvement. The early start of an intensive multi-agent chemotherapy resulted in complete disease remission. At 60 months after the diagnosis, the patient is alive and has not had any recurrence. CONCLUSIONS: Clinicians should be aware that thyroid Burkitt's lymphoma is an aggressive disease that needs to be treated with multi-agent chemotherapy as soon as possible. To diagnose it promptly, they should consider to order/perform a CNB in any patient with a rapidly enlarging thyroid mass that is suspicious for lymphoma.


Assuntos
Linfoma de Burkitt/patologia , Glândula Tireoide/patologia , Neoplasias da Glândula Tireoide/patologia , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Biópsia com Agulha de Grande Calibre/métodos , Linfoma de Burkitt/diagnóstico por imagem , Feminino , Humanos , Pessoa de Meia-Idade , Glândula Tireoide/diagnóstico por imagem , Glândula Tireoide/efeitos dos fármacos , Neoplasias da Glândula Tireoide/diagnóstico por imagem , Neoplasias da Glândula Tireoide/tratamento farmacológico , Nódulo da Glândula Tireoide/diagnóstico por imagem , Nódulo da Glândula Tireoide/tratamento farmacológico
4.
Endocrine ; 57(3): 402-408, 2017 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-27848197

RESUMO

PURPOSE: Radiofrequency ablation has been advocated as an alternative to radioiodine and/or surgery for the treatment of autonomously functioning benign thyroid nodules. However, only a few studies have measured radiofrequency ablation efficacy on autonomously functioning benign thyroid nodules. The aim of this work was to evaluate the 12-month efficacy of a single session of radiofrequency ablation (performed with the moving shot technique) on solitary autonomously functioning benign thyroid nodules. METHODS: Thirty patients with a single, benign autonomously functioning benign thyroid nodules, who were either unwilling or ineligible to undergo surgery and radioiodine, were treated with radiofrequency ablation between April 2012 and May 2015. All the patients underwent a single radiofrequency ablation, performed with the 18-gauge needle and the moving shot technique. Clinical, laboratory, and ultrasound evaluations were scheduled at baseline, and after 1, 3, 6, and 12 months from the procedure. RESULTS: A single radiofrequency ablation reduced thyroid nodule volume by 51, 63, 69, and 75 % after 1, 3, 6, and 12 months, respectively. This was associated with a significant improvement of local cervical discomfort and cosmetic score. As for thyroid function, 33 % of the patients went into remission after 3 months, 43 % after 6 months, and 50 % after 12 months from the procedure. This study demonstrates that a single radiofrequency ablation allowed us to withdraw anti-thyroid medication in 50 % of the patients, who remained euthyroid afterwards. CONCLUSION: This study shows that a single radiofrequency ablation was effective in 50 % of patients with autonomously functioning benign thyroid nodules. Patients responded gradually to the treatment. It is possible that longer follow-up studies might show greater response rates.


Assuntos
Técnicas de Ablação/efeitos adversos , Hipertireoidismo/prevenção & controle , Hipotireoidismo/prevenção & controle , Terapia por Radiofrequência , Glândula Tireoide/cirurgia , Nódulo da Glândula Tireoide/cirurgia , Idoso , Estudos de Coortes , Feminino , Seguimentos , Humanos , Hipertireoidismo/etiologia , Hipotireoidismo/etiologia , Itália , Masculino , Gradação de Tumores , Tratamentos com Preservação do Órgão/efeitos adversos , Aceitação pelo Paciente de Cuidados de Saúde , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/prevenção & controle , Estudos Prospectivos , Ondas de Rádio/efeitos adversos , Indução de Remissão , Glândula Tireoide/irrigação sanguínea , Glândula Tireoide/diagnóstico por imagem , Glândula Tireoide/fisiopatologia , Nódulo da Glândula Tireoide/irrigação sanguínea , Nódulo da Glândula Tireoide/diagnóstico por imagem , Nódulo da Glândula Tireoide/fisiopatologia , Carga Tumoral/efeitos da radiação , Ultrassonografia
5.
J Diabetes Res ; 2016: 8917578, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27652272

RESUMO

Since the advent of insulin, the improvements in diabetes detection and the therapies to treat hyperglycemia have reduced the mortality of acute metabolic emergencies, such that today chronic complications are the major cause of morbidity and mortality among diabetic patients. More than half of the mortality that is seen in the diabetic population can be ascribed to cardiovascular disease (CVD), which includes not only myocardial infarction due to premature atherosclerosis but also diabetic cardiomyopathy. The importance of renin-angiotensin-aldosterone system (RAAS) antagonism in the prevention of diabetic CVD has demonstrated the key role that the RAAS plays in diabetic CVD onset and development. Today, ACE inhibitors and angiotensin II receptor blockers represent the first line therapy for primary and secondary CVD prevention in patients with diabetes. Recent research has uncovered new dimensions of the RAAS and, therefore, new potential therapeutic targets against diabetic CVD. Here we describe the timeline of paradigm shifts in RAAS understanding, how diabetes modifies the RAAS, and what new parts of the RAAS pathway could be targeted in order to achieve RAAS modulation against diabetic CVD.


Assuntos
Bloqueadores do Receptor Tipo 2 de Angiotensina II/uso terapêutico , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Aterosclerose/tratamento farmacológico , Doenças Cardiovasculares/tratamento farmacológico , Cardiomiopatias Diabéticas/tratamento farmacológico , Aterosclerose/etiologia , Aterosclerose/prevenção & controle , Doenças Cardiovasculares/etiologia , Doenças Cardiovasculares/prevenção & controle , Cardiomiopatias Diabéticas/prevenção & controle , Humanos
6.
BMC Nephrol ; 17(1): 65, 2016 07 07.
Artigo em Inglês | MEDLINE | ID: mdl-27389397

RESUMO

BACKGROUND: Malignant hypertension is a condition characterized by severe hypertension and multi-organ ischemic complications. Albeit mortality and renal survival have improved with antihypertensive therapy, progression to end-stage renal disease remains a significant cause of morbidity and mortality. The underlying cause of malignant hypertension, which can be primary or secondary hypertension, is often difficult to identify and this can substantially affect the treatment outcomes, as we report here. CASE PRESENTATION: A 33-year-old woman presented with severe hypertension and acute renal failure. Initial evaluation demonstrated hyperreninemia with hyperaldosteronism and a possible renal artery stenosis at the contrast-enhanced CT scan. Although this data suggested the presence of a secondary form of hypertension, further exams excluded our first diagnosis of renal artery stenosis. Consequently, the patient did not undergo renal angiography (and the contrast media infusion associated with it), but she continued to be medically treated to achieve a tight blood pressure control. Our conservative approach was successful to induce renal function recovery over 2 years of follow-up. CONCLUSION: This case highlights the difficulty in differentiating between primary and secondary forms of malignant hypertension, particularly when the patient presents with acute renal failure. Clinicians should consider renal artery ultrasound as a first level diagnostic technique, given that the presentation of primary malignant hypertension can often mimic a renal artery stenosis. Secondly, adequate control of blood pressure is essential for kidney function recovery, although this may require a long time.


Assuntos
Injúria Renal Aguda/etiologia , Hipertensão Essencial/complicações , Hipertensão Maligna/complicações , Hipertensão Maligna/diagnóstico , Adulto , Anti-Hipertensivos/uso terapêutico , Hipertensão Essencial/tratamento farmacológico , Feminino , Humanos , Hiperaldosteronismo/sangue , Hipertensão Maligna/tratamento farmacológico , Renina/sangue
7.
J Renin Angiotensin Aldosterone Syst ; 16(4): 730-8, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26283678

RESUMO

OBJECTIVE: Experimental evidence suggests that aldosterone directly contributes to organ damage by promoting cell growth, fibrosis, and inflammation. Based on these premises, this work aimed to assess the glomerular effects of aldosterone, alone and in combination with salt. METHODS: After undergoing uninephrectomy, 75 rats were allocated to five groups: control, salt diet, aldosterone, aldosterone + salt diet, aldosterone + salt diet and eplerenone, and they were all studied for four weeks. We focused on glomerular structural, functional, and molecular changes, including slit diaphragm components, local renin-angiotensin system activation, as well as pro-oxidative and profibrotic changes. RESULTS: Aldosterone significantly increased systolic blood pressure, led to glomerular hypertrophy, mesangial expansion, and it significantly increased the glomerular permeability to albumin and the albumin excretion rate, indicating the presence of glomerular damage. These effects were worsened by adding salt to aldosterone, while they were reduced by eplerenone. Aldosterone-induced glomerular damage was associated with glomerular angiotensin-converting enzyme (ACE) 2 downregulation, with ACE/ACE2 ratio increase, ANP decrease, as well as with glomerular pro-oxidative and profibrotic changes. CONCLUSIONS: Aldosterone damages not only the structure but also the function of the glomerulus. ACE/ACE2 upregulation, ACE2 and ANP downregulation, and pro-oxidative and profibrotic changes are possible mechanisms accounting for aldosterone-induced glomerular injury.


Assuntos
Aldosterona/farmacologia , Glomérulos Renais/patologia , Glomérulos Renais/fisiopatologia , Animais , Fibrose , Taxa de Filtração Glomerular/efeitos dos fármacos , Glomérulos Renais/efeitos dos fármacos , Masculino , Oxirredução/efeitos dos fármacos , Estresse Oxidativo/efeitos dos fármacos , Ratos Wistar , Sistema Renina-Angiotensina/efeitos dos fármacos , Cloreto de Sódio na Dieta/farmacologia
8.
GED gastroenterol. endosc. dig ; 14(5): 229-35, set.-out. 1995. tab
Artigo em Português | LILACS | ID: lil-178567

RESUMO

Os autores fazem revisao dos critérios de prognósticos utilizados na pancreatite aguda, enfatizando a importância do conjunto de avaliaçoes clínico-laboratoriais e de imagem. Muitos dos diferentes critérios avaliados utilizam parâmetros comuns, para outros eles sao próprios. Discute-se qual o melhor método a ser empregado em paciente com pancreatite aguda, visando estabelecer o tratamento mais adequado e desse modo evitar a utilizaçao desnecessária de recursos e contribuir para a padronizaçao da conduta médica.


Assuntos
Humanos , Pancreatite/diagnóstico , Doença Aguda , Prognóstico , Índice de Gravidade de Doença
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA